Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PsiOxus to Release Study Results of Oncolytic Vaccine Enadenotucirev

Published: Saturday, May 17, 2014
Last Updated: Saturday, May 17, 2014
Bookmark and Share
Phase I studies to be presented at 2014 ASCO annual meeting.

PsiOxus Therapeutics, Ltd. (PsiOxus) has announced that two of its on-going phase I studies of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting to be held 30 May to 3 June, 2014 in Chicago, Illinois.

The EVOLVE (EValuating OncoLytic Vaccine Efficacy) trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers and the MoA (Mechanism of Action) trial is a phase I “window of opportunity” trial evaluating intravenous and intra-tumoural administration of enadenotucirev to patients with colon cancer.

Enadenotucirev is an oncolytic Ad11/Ad3 chimeric group B adenovirus that has previously been shown to selectively destroy metastatic solid tumours at low concentrations in pre-clinical models.

To date, a combined total of 46 cancer patients have been dosed with up to four cycles (12 doses) of enadenotucirev. An independent Data Safety Monitoring Committee has approved the proposed dose to be taken into phase 2 clinical trials for both single cycle and repeat cycle administration. This safety data will be presented at the ASCO meeting.

Intra-tumoural delivery of oncolytic viruses to superficial tumour sites has been shown to be clinically successful in phase III clinical trials, but systemic delivery of viruses to metastatic tumour sites via intravenous delivery has been more elusive.

In the two PsiOxus studies, the ability to selectively deliver the live replicating virus to tumour cells has been examined by a number of techniques including positron emission tomography scans, immunohistochemistry, quantitative polymerase chain reaction assays, and viral plaque assays.

• Dr Emiliano Calvo will present A First in Human Phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumours (poster board 170) at ASCO on Sunday, June 1 in S Hall A2 from 8:00 a.m. to 11:45 a.m.

• Dr Rocio Garcia Carbonero will present Phase 1 Mechanism of Action Study of Intra-tumoral or Intravenous Administration of enadenotucirev, an Oncolytic Ad11/Ad3 Chimeric group B Adenovirus in Colon Cancer Patients Undergoing Resection of Primary Tumour (poster board 178B) at ASCO on Sunday, June 1 in S Hall A2 from 8:00 a.m. to 11:45 a.m.

Dr John Beadle, CEO of PsiOxus, commented: “We are looking forward to the presentation of these clinical study results as we assess the safety profile of enadenotucirev as well as intravenous delivery of this oncolytic vaccine to cancer cells in patients. We remain on track to initiate phase II study later this year.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Myotec Merges with Hybrid Biosystems to Form PsiOxus Therapeutics
Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces the merger of its portfolio company Myotec Therapeutics Ltd. (Myotec) with Hybrid Biosystems Ltd. (Hybrid) to form PsiOxus Therapeutics.
Wednesday, December 15, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Researchers Resurrect Ancient Viruses
Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina.
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!